Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
Porky, I guess the proof will be in the (Xmas) pudding. As you say, not long to wait. !p-2p by Christmas Day as per your festive prediction on 25/9/23.
At no point have I ever claimed everything is rosy in the garden. Clearly many mistakes have been made over the past 2 years and my own posts acknowledge that. However, I cannot the life of me fathom why you would spend so long on this forum with such negativity when your own ‘mission statement’ criticises those who commit that very act.
Perhaps you feel you’re obliged to save us all from our fate so you can sleep at night. Admirable, though entirely unnecessary. We all known the risks of investing, particularly in Aim. I accept your disastrous experiences with 4D, NCYT, HE1, SNT, INSP, etc give you an advantageous insight into companies NOT to invest in and I thank you for your concern but I’m a big boy and I’ll take my chances where I see fit.
PS. OB, If things do eventually work out and we happen to eventually meet on some Greek island, can I have your autograph. You have always struck me as a genuine bloke who has put his hard-earned cash into a worthy cause hoping to make a few quid along the way! I'll be driving a yellow Maserati and the drinks are on me!
As regards your claim of outdated comments, in your own words: "I just can't abide negativity, can't stand it at any level. I can kind of get it if its to put off investors to try and get a cheaper price, i don't agree with the practice, but i get it."
This is exactly what you are doing every day when you post on VAL. Nothing historical about that. Reread your posts today, yesterday, last week, last month, whenever.
We all make mistakes in our investing, particularly in the minefield of Aim companies. I don’t like to see anyone, even yourself, lose money on the stock market. However, this blatant ramping/de-ramping to suit your agenda at any one time needs calling out, particularly when you then slate others for promoting a particular share they believe in.
There are clearly two distinct camps on this forum and we will soon know any outcome. Tears WILL be shed, whether holders who suffer a significant dilution or others, like yourself who will look at the sunny uplands only to think what might have been. I know which camp I’ve settled in. Champagne anyone?
Just thought my fellow investors would like a glimpse into the mindset of our resident pig, A genuine quote copied and pasted verbatim.
"I just can't abide negativity, can't stand it at any level. I can kind of get it if its to put off investors to try and get a cheaper price, i don't agree with the practice, but i get it."
Posted by Porky in......you guessed it,` Valirx on 30/10/21.`
Suzy is confident and unconcerned. Porky is desperate and confused.
I took a small position here a week ago following the impressive half-year results. The SP just looked too inviting for a company with 94% of shares held by institutions and a P/E around 15.
Sky are now reporting Apax Partners are back in for the WGSN slice "with discussions at an advanced stage". Their original enquiry earlier this year was in the region of £700m but now expected to be substantially below. Nevertheless, with an ASCL mkt cap of less than £1b, it could well see a significant sum deposited in the company coffers.
I took a couple of small top-ups this morning from divis elsewhere. Following yesterday's Q&A, Adam's X positivity and to top it all, Porky's desperation, it just seems like all the stars are aligned!
Like all genuine holders I am appalled at the current SP. Most of us will be holding at multiples of the current price. However, no devastating RNS has just been released and no more shares recently been issued. Each of us still owns the same percentage of the company, proportionate to our holding, as we did some months ago. Yes, the market value of those shares has tumbled but that is not a financial loss unless holders sell to crystallise that loss.
Like many others, I wait in anticipation every morning for a 7am RNS which justifies our perseverance in Valirx. Another day passes and no news. However, there are many SHs with significantly greater holdings and probably at a considerably higher average than my own. While Adam may not be ‘inside’ you can be sure he is a keen observer of how the company is operating and using his past experience to ‘suggest’ any improvements the Board may consider. He remains the largest holder and as such has the most to lose in the event of any lack of progress. He also will not sit by twiddling his thumbs if he does not see the progress or effort we all demand. Nice bloke or not, he did not become a successful entrepreneur without making ruthless decisions when necessary.
I do not consider myself a ramper. I have been critical of management in the past and some of the extraordinary poor choices they have made. However, we are where we are and until that low-ball placing arrives I remain hopeful, though maybe not overly confident, that it might instead be a RNS that brings a long overdue smile to our faces. I certainly think we deserve it!
Well, our resident porcine chap has now stated (24/9/23 @ 23.19) that the very best we can hope for is a 1p/2p placing within the next 3 months. Yes, this is the very chap who has lost a fortune in earlier Aim ventures and still thinks of himself as Warren Buffet reinvented. The same speculator who is now advising Dr Adam Hargreaves, a successful entrepreneur with a highly-qualified scientific background, to cut his losses and get out prior to the giveaway placing.
I only mention this particular post by Porky so I can refer back to it on Christmas Day when the 3 months have passed. I am sure most long-term holders will enjoy seeing our Mr Bacon with egg on his face.
Screams of delight could be heard coming from the offices of Avacta and Scancell.
Meanwhile, in a sleepy biolab in Nottingham, “zzzzzzz. Turn that bloody light off! zzzzzzz”.
Agreed. This may have been in the pipeline for a few weeks but Adam's commercial acumen could already be evident.
I certainly hope so as it bodes very well if that is the case!
Porky is clearly a well-educated and eloquent poster. To those genuine holders who defend his viewpoints ask yourself why he would spend so much time trying to deride Val if, as he claims, he is still holding. Either he hasn’t got the hang of ramping or he has an ulterior motive.
According to his crystal ball, a 5p or lower placing is imminent yet he continues to hold? Any genuine shareholder with such conviction would sell to buy back at the lower price. A different agenda becomes apparent.
All his posts (an unbelievable 79 just in the last month!) have the clear objective of unsettling Val holders in the hope of getting them to sell and drive the SP lower. Like many of us, this individual must see amazing potential in Val to spend his time continually berating the share in the hope of entering at an even lower price. We all know he is desperate to recoup some of the massive losses following his earlier crazy ventures into the stock market.
I accept there have been many mistakes made by the BOD which have resulted in our current shameful SP but believe Adam’s appointment will be the spark to ignite Val. By all means be critical of previous Board failings but be wary of giving any credence to someone who is desperate to profit at your expense.
Porky, I hate to destroy your illusion but Warren Buffet you ain’t. Your LSE track record of share failures is appalling and there for all to see. To then continually post your opinions, advise where the company is failing and criticise others on this board is frankly laughable.
At first you were 3/10 for entertainment value but now just an annoying little piglet. Poor old Peppa wonders are you ever going to bring home the bacon?
Sorry about the lack of capitals. Phone playing up.
i was disappointed that there were no bod changes at the recent agm. adam joining the board in a senior position would have been the ideal scenario but we are not privy to his personal circumstances and the time commitments would probably have been too demanding. still, as a fallback, his advisory position has to be taken as a big plus. he has the most to lose of all val holders and obviously feels he can have a positive influence on future decisions in this role. in voting to support the existing board he clearly believes stability is the key to eventual sp growth.
there has been a lot of in-******** on this forum which can do little to either entice new investors or show support for the current management. clearly much of it is agenda-driven, whether pm's ramping when genuine positives are in short supply or porky's desperate attempts to influence shs to sell by constantly claiming a giveaway raise is imminent. as an investor, i want nothing more than the sp to head north but accept there is nothing i can do (or afford to do) to expedite that happening.
most fellow investors post to simply vent their frustrations at the diminishing sp and who can blame them. suzy has made some very poor decisions over the last 18 months to our detriment. we are invested in a venture which has the potential to make significant advances in cancer research and hoping to make a decent profit along the way, yet most of us are underwater to varying degrees. even wannabees like porky can see the potential or why waste hours posting daily deridng the share in a pathetic attempt to drive the price even lower. i must admit to having a laugh at nick slater's tongue-in-cheek suggestion of clueless porky joining the board. peppa has more business acumen. 😀
i am optimistic now that with adam's expertise and guidance we can eventually fulfil our potential and when our financial position improves, capitalise on market opportunities within our budget. we are far from the only microcap with a struggling sp. there are many aim shares vying for limited funds in the current macro environment. we may need a bit more patience for general market conditions to improve before we see any significant advances in the sp. however, with adam's influence pending i believe the bod have taken, albeit long overdue, what will prove to be a shrewd decision for the future of valirx
Two months ago, I decided that unless the SP was in the mid-teens by the AGM I would vote for change. It would be daft to keep the status quo and expect a significant turnaround. I respect Adam Hargreaves’ opinion enormously and recently he requested we wait until after the Q&A before making any voting choices. Having watched yesterday’s presentation and considering recent developments, I have seen nothing to suggest anything other than a continued decline in the SP under the tenancy of the current BOD. At no point have they inspired belief that a major rerate is imminent.
Yesterday was just an exercise in RS-covering in a pathetic attempt to justify each individual’s BOD position despite an 80% SP collapse over the last 30 months. A significant team rebuild is required if we are to see any major SP increase in the short to mid-term. Stability is all very well if there are signs the team are on the cusp of a major breakthrough. I see no such thing. Without personal investment, Stella brings nothing to the team. She can go.
The lack of BOD investment is the prime indicator that all is not rosy in Val. Similarly, the clear reluctance to have Adam on the board confirms they do not want a major shareholder having any significant influence in business decisions. Obviously, it could adversely impact on Suzy’s empire-building aspirations. Ideally, Suzy remains as CEO but I hope she views the voting as a reflection of our dissatisfaction with her performance to date.
I agree with Nick Slater that Gerry and Martin’s time is up. By keeping Suzy and Kevin we retain the general direction and their belief in the potential of our legacy products and new compounds. They also will have developed alliances which should prove beneficial when dealing with universities and the like.
If Suzy is unfortunately voted out as CEO she may consider a CSO position but she is far from indispensable. If she throws her toys out then que sera. She and the BOD have ignored our concerns for far too long.
Porky, let's face it, if I only had 10 shares in Val, it's 10 more than you have!!!!!!
Good to hear from you Adam.
My sentiments exactly, though I have to admit my vote is still in the balance depending how things pan out over the next week or so.
Investors are here to make money, some short-term, some long. Suzy doesn’t appreciate the frustration of supporting a company thru’ lean years only to see latecomers benefit from significantly discounted placings. Furthermore, such fundraising inevitably attracts short-term profiteers and the subsequent volatility of the SP. For over two years Suzy has been promoting our products and informing us how well the various projects are advancing yet the SP does not reflect progress. On the contrary, we have seen an 80% fall since the LOI RNS in Nov ’21.
Regarding the long-standing TRX 201 debacle, in Dec ‘22 Suzy confirmed “if insufficient progress towards funding seen at any time the exclusivity agreement will be terminated”. We have not been informed of any termination so can only conclude she HAS seen sufficient progress and we can at last look forward to a detailed summary of such. She has previously stated that this information is commercially sensitive and shareholders will not be informed until it becomes “fully public knowledge”. Fine, release an RNS giving an update of where we stand. You cannot tease investors with tweets and comments suggesting good progress, yet 18 months following the LOI we are still completely in the dark. Time to let the sun shine through!
Many differing opinions/suggestions as we approach the AGM regarding the best way forward for VAL. There appears unanimous agreement that some change is required. However, in functional areas where it isn’t broken…..
From a research and development perspective, Suzy, Cathy, Zai and most informed fellow investors clearly have great belief in our bio-portfolio. The company appears to excel in creating quality products but then struggles to capitalise on their potential. Cancer research is a very competitive arena but the potential gains are astronomical. Many bio/pharma will fall by the wayside but for those that achieve any degree of success the possibilities and rewards are limitless. Most low caps bios have a single product. We have multiple and it only needs one successful take-up to propel us upwards and all the rewards that would entail.
However, promoting and marketing those same products is a concern and a significant weakness within the company. A fresh perspective in this area is clearly needed. Dr Dilly may be a brilliant scientist but this is not her forte and she is not receiving the support required from her colleagues.
Secondly, our CEO either doesn’t understand market forces or considers them insignificant. A major failing in such a key position. For Suzy to be successful in the CEO role she clearly needs strong guidance in this respect. If she had been less naïve and better advised at earlier key junctures it is likely our finances would be in a far healthier position. The less said about Cenkos the better.
Finally, whether in her RNS, tweets or Q&A sessions, Suzy talks of the science, staffing, future plans and bio market events but the SP appears a minor consideration. And therein lies the difference to our viewpoints! Dr Dilly seems to believe this is a sponsorship arrangement for her pet project. She simply does not ‘get’ the SP significance. Why would she? With such a comparatively minor holding there is no direct correlation between her personal financial position and the current SP. She still receives her salary and her project continues regardless. When eventually there is a major advance in the SP further rewards will kick in but at the lower SPs they are irrelevant.
The above concerns could all be resolved by Adam’s involvement as a director in some influential capacity. He can call on his own experience to make suggestions, identify and evaluate market opportunities and help steer board decisions away from the incompetence which has trashed the SP. More importantly, he has overwhelming support from the majority of shareholders. Both individuals are enthusiastic and extremely optimistic regarding the future but Adam’s interests align directly with our own whereas Suzy’s are from an empire-building perspective. Simply announcing his appointment would probably boost the stagnant SP by over 10%.
As an investor, primarily I assess Dr Dilly’s CEO performance by the current SP. In that respect she has failed miserably. We are now approaching the AGM, the share price is still languishing around 10p and the silence is deafening regarding significant progress on any of our lead products.
Many LTHs will recall the dark days of early 2020 when Valirx were teetering on the brink. Indeed on 17th Feb that year the company issued an RNS advising it only had funds to last a further 6 weeks. Thankfully, we survived that scare and Suzy, was promoted to CEO in June 2020, making significant progress in the early days. However, she has since made some critical errors during her tenure.
The original Letter of Intent with TheoremRX was announced by RNS on 2/11/21. Prior to the release the SP was 52p. Following the RNS it dropped to 34p and has pretty much been in decline ever since. Surely our CEO could have envisaged the likely impact of announcing a potential deal involving one of Valirx’s prime assets to an unknown start-up.
Suzy would have been continually aware of the company’s financial position yet she waited until the SP had fallen to 16p in June ’22 before announcing a 10p fundraise, resulting in considerably dilution to almost all holders at that time.
Over the last 2 years her beloved twitterings include “…..a deal with TRX worth up to over $61m in near-term payments” (to coincide with the LOI RNS on 2/11/21). When there were later murmurs of discontent at slow progress we got the renowned “totally confident and unconcerned” tweet. Although not an official RNS, such positivity from the CEO undoubtably has an impact on how PIs view the company. I’m not alone in reading those tweets and believing a major deal must be imminent. In reality we were led up the garden path on more than one occasion.
Several contributors to this forum have criticised Dr Kevin Cox’s input to the current SP fiasco and while that may be justified, as CEO Suzy carries the can. If other members of the management team are not up to the job then she needs to remove the chaff. The buck stops with Suzy.
My belief in Dr Dilly as a scientist and valuable member of the team remains. However, for me, her leadership skills are very limited. She has had ample time to bring at least one of our prime compounds to fruition yet, barring the proverbial rabbit, the prospect of yet a further fundraise beckons. As a developing company in AIM, I accept that goes with the territory but not at these rock bottom SPs. I expect to see SP growth and fundraises at a premium price as new investors scramble to get their foot in the door.
With little personal financial commitment, Suzy appears only interested in developing her Valirx project, regardless of how it impacts the SP. Investors are a nuisance to be humoured and pacified. While admiring the focus of Valirx’s work, I have invested here to make a profit, not just to fund a scientist’s dream. In this respect. There seems a clear conflict between her interests and ours.
Only another few weeks and we get the opportunity to make a significant change in how Valirx is managed. Ideally, like most on this forum, I would love to see Adam at the helm but I accept that may be too demanding as he has other commitments. However, just to have him as a director would give a massive boost to investor confidence and assist in steering the company to profitability in a much shorter time frame. With significant skin in the game Adam would obviously have a direct interest in the SP.
I ask Adam to consider promoting himself as a potential director in whatever capacity he feels he could commit to. He will have undoubtedly considered this as he has been one of those hit hardest by the current SP. I have no doubt he would gain tremendous support from the shareholder base. Nick Slater has indicated on several occasions that he would welcome Adam’s addition to the board. The snag is we would lose Dr Hargreaves valuable contributions to this forum. Nevertheless, as we see the SP rise with each passing month, I’m sure we would soon come to terms with that setback!